H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on OncoSec Medical (NASDAQ: ONCS) today and set a price target of $4. The company’s shares closed yesterday at $1.25.
Selvaraju noted:
“We believe the analysis should provide insights on the genetic and epigenetic mechanisms that correspond to specific clinical outcomes in melanoma patients. In addition, such knowledge could be applied to other indications TAVO may address, such as triple-negative breast cancer (TNBC) being targeted in the KEYNOTE-890 Phase 2b trial. In the wake of this update, we reiterate our Buy rating and $4 price target on ONCS. Clinical catalysts approaching in 2H18.”
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -2.8% and a 34.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on OncoSec Medical is a Moderate Buy with an average price target of $4.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.95 and a one-year low of $0.88. Currently, OncoSec Medical has an average volume of 561.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications.
